Welcome to our dedicated page for Qrons news (Ticker: QRON), a resource for investors and traders seeking the latest updates and insights on Qrons stock.
QRons Inc., a preclinical stage biotechnology company, focuses on developing stem cell synthetic hydrogel-based solutions to combat neuronal injuries, particularly traumatic brain injuries. The company's product candidates include QS100, an injury-specific, 3D printable, implantable modified mesenchymal stem cells (MSCs)-synthetic hydrogel to treat penetrating brain injuries, and QS200, an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries. QRons Inc. has a license and research funding agreement with Ariel University R&D Co., Ltd. for the development and commercialization of products for neuronal tissue regeneration and repair.
Formerly known as Biolabmart Inc., QRons Inc. changed its name in August 2017. The company, founded in 2016, is based in New York, New York.
Qrons Inc. (OTCQB:QRON) has filed an International Patent Application for its innovative Therapeutic Polypseudorotaxane Hydrogels, aimed at treating traumatic brain injuries and other nervous system conditions. Filed on March 12, 2023, the patent application number is PCT/IB2023/052368. The technology promises to support neuronal damage treatment and regeneration, with potential applications extending beyond traumatic brain injuries. CEO Jonah Meer emphasizes the significance of this filing in advancing their intellectual property and research initiatives. Qrons focuses on strategic partnerships to enhance its biotechnology developments, particularly in Israel, known for its biotech innovations.
Qrons Inc. (OTCQB:QRON) has announced a collaboration with a major public research university in Israel to explore the therapeutic potential of Tellurium-based compounds alongside its QS200 product candidate for treating diffused axonal injuries, responsible for most traumatic brain injuries. Preliminary studies indicate positive effects against antibiotic-resistant bacteria and sepsis. Qrons plans to advance to pre-clinical and pilot clinical studies to validate findings and expand its intellectual property. The CDC highlights the urgency of addressing these medical conditions, with significant hospitalization and mortality rates.
Qrons Inc. (OTCQB:QRON) announced on April 3, 2022, the filing of a United States Provisional Patent Application for Therapeutic Polypseudorotaxane Hydrogels. This patent aims to provide global protection for inventions targeting central nervous system conditions like traumatic injuries and neurodegenerative diseases. President Ido Merfeld emphasized that the filing reflects their innovative research in neuronal tissue engineering. CEO Jonah Meer stated this patent enhances their intellectual property portfolio and supports their QS200 product candidate development.
Qrons Inc. (OTCQB:QRON) has received SEC approval for its Post-Effective Amendment to the S-1 Registration Statement, which enables an offering of up to 2.5 million shares. This follows the original filing on December 1, 2021. The funds raised will be directed toward advancing technology for neuronal diseases, sales and marketing, patent filing, and general working capital. CEO Jonah Meer stated that these efforts aim to enhance shareholder structure and increase liquidity, supporting plans for a future uplisting. Qrons also emphasizes ongoing commitments to ensure the registration statement remains current.
Qrons Inc. (OTCQB:QRON) announced that the USPTO granted U.S. Patent No. 10,954,315 to Dartmouth College, covering 3-D printing materials. This patent results from Qrons' collaboration with Professor Chenfeng Ke since July 2018, focused on developing 3D printable hydrogels for its stem cell-based treatments for traumatic brain injuries. The exclusive license from Dartmouth allows Qrons to leverage these advancements in its biotech innovations. CEO Jonah Meer emphasized the importance of this step in enhancing Qrons' technological foundation.
FAQ
What is the market cap of Qrons (QRON)?
What is QRons Inc.'s focus?
What are the product candidates of QRons Inc.?
Who does QRons Inc. have a licensing agreement with?
When was QRons Inc. founded?
Where is QRons Inc. based?
What is the history behind QRons Inc.'s name change?
